Stanford University
Showing 31-40 of 48 Results
-
Matthew Bogyo
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:
1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.
2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.
3) Defining the specific functional roles of proteases during the process of tumorogenesis.
4) In vivo imaging of protease activity -
Sam Bollinger
Ph.D. Student in Cancer Biology, admitted Autumn 2021
BioOriginally from State College, Pennsylvania, Sam graduated with honors from Penn State University with a B.S. in Chemistry and a minor in Biology. He subsequently spent three years working at the Lankenau Institute for Medical Research for Dr. Ellen Heber-Katz. Sam hopes to expand the paradigm of cancer research and help to develop novel therapies for cancer and other ailments. He is also interested in optimization of physical and mental performance.
-
Melissa L Bondy
Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsPrincipal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)
Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)
Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023
Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22
Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025 -
Donna M. Bouley, DVM, PhD
Professor of Comparative Medicine at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsResearch interests: ocular pathology, host-pathogen interactions in infectious disease, infectious disease in frogs, phenotypic characterization of tg and ko mice, histopathology of minimally-invasive radiological ablation techniques (focused ultrasound, cryoablation).
-
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.
-
Scott D. Boyd, MD PhD
Stanford Professor of Food Allergy and Immunology and Professor of Pathology
Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.
-
Onn Brandman
Associate Professor of Biochemistry and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsThe Brandman Lab studies how cells sense and respond to stress. We employ an integrated set of techniques including single cell analysis, mathematical modeling, genomics, structural studies, and in vitro assays.
-
James D. Brooks
Keith and Jan Hurlbut Professor
Current Research and Scholarly InterestsWe use genomic approaches to identify disease biomarkers. We are most interested in translating biomarkers into clinical practice in urological diseases with a particular focus in cancer.
-
Martin Brown
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsWe seek to understand the mechanisms responsible for the resistance of cancers to treatment and to develop strategies to overcome these resistances. We are using molecular and cellular techniques and mouse models to potentiate the activity of radiation on tumors by inhibiting the bone marrow rescue of the tumor vasculature following therapy.